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ABSTRACT Recently genome-wide association studies have identiﬁed signiﬁcant association between
Alzheimer’s disease (AD) and variations in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33,
EPHA1,a n dABCA7. However, the pathogenic variants in these loci have not yet been found. We conducted
a genome-wide scan for large copy number variation (CNV) in a dataset of Caribbean Hispanic origin (554
controls and 559 AD cases that were previously investigated in a SNP-based genome-wide association study
using Illumina HumanHap 650Y platform). We ran four CNV calling algorithms to obtain high-conﬁdence calls
for large CNVs (.100 kb) that were detected by at least two algorithms. Global burden analyses did not
reveal signiﬁcant differences between cases and controls in CNV rate, distribution of deletions or duplications,
total or average CNV size; or number of genes affected by CNVs. However, we observed a nominal associ-
ation between AD and a  470 kb duplication on chromosome 15q11.2 (P = 0.037). This duplication, encom-
passing up to ﬁve genes (TUBGCP5, CYFIP1, NIPA2, NIPA1,a n dWHAMML1) was present in 10 cases (2.6%)
and 3 controls (0.8%). The dosage increase of CYFIP1 and NIPA1 genes was further conﬁrmed by quantitative
PCR. The current study did not detect CNVs that affect novel AD loci identiﬁed by recent genome-wide
association studies. However, because the array technology used in our study has limitations in detecting
small CNVs, future studies must carefully assess novel AD genes for the presence of disease-related CNVs.
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Alzheimer’s disease (AD) is the most common form of dementia, af-
fecting  30% of individuals over 80 years of age (Mayeux 2003). The
hallmark of AD brain pathology is characterized by the accumulation
of a neurotoxic proteolytic derivative of the amyloid precursor protein
(APP; Ab peptides) and the formation of intraneuronal tau-associated
neuroﬁbrillary tangles. The majority of AD cases are sporadic ( 95%),
with onset after 65 years of age. One half of the genetic variance is
attributable to mutations in APP, PSEN1, PSEN2, and the APOE e4-
allele, and they have been shown to cause the overproduction or
reduced clearance of Ab (Rogaeva et al. 2006). More recently, it was
demonstrated that single nucleotide polymorphisms (SNP) in SORL1
are signiﬁcantly associated with late-onset AD in several indepen-
dent cohorts (Rogaeva et al. 2007; Reitz et al. 2011). In addition,
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sets have identiﬁed signiﬁcant association between late-onset AD
and SNPs in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP,
CD33, EPHA1, and ABCA7 (Harold et al. 2009; Lambert et al. 2009;
Carrasquillo et al. 2010; Hollingworth et al. 2011; Naj et al. 2011).
Our recent GWAS of a Caribbean Hispanic cohort has supported
the association with SNPs in the CLU, PICALM, and BIN1 genes
(Lee JH et al. 2010). However, the pathogenic variants in these novel
AD loci have not yet been found.
Copy number variants (CNV) have been associated with several
neuropsychiatric disorders, such as autism, schizophrenia, and bipolar
disorder (Cook and Scherer 2008; Lee and Scherer 2010). Furthermore,
rare duplications of the APP locus are associated with dominant early-
onset AD, which support the possibility of the existence of disease-
related CNVs in other AD genes (McNaughton et al. 2010). In fact,
recently Brouwers et al. proposed that the association between CR1
and AD might be explained by intragenic CNVs that translate into two
major CR1 isoforms (Brouwers et al. 2011). To date, there are only two
published genome-wide case-control studies that assess the contribu-
tion of CNVs to AD in North American populations (Heinzen et al.
2010; Swaminathan et al. 2011). However, in both studies, CNV calls
were detected using a single method (PennCNV), and no overall case-
control differences were observed in the CNV rate, size, presence of
rare genic CNVs, or number of genes disrupted by CNVs. The only
borderline association was reported by Heinzen et al. for a  500 kb
duplication at 15q13.3 affecting the CHRNA7 gene that encodes the
neuronal nicotinic cholinergic receptor (P ¼ 0.053, uncorrected for
multiple testing) (Heinzen et al. 2010).
To evaluate the contribution of rare genomic variants to risk of late-
onset AD, we analyzed a Caribbean Hispanic dataset that was previ-
ously assessed in a SNP-based GWAS (Lee JH et al.2 0 1 0 ) .W ef o c u s e d
our investigation on large rare CNVs that might contribute signiﬁ-
cantly to disease risk, as was previously demonstrated in other neuro-
psychiatric disorders (Kirov et al. 2009; Zhang et al. 2009; Glessner
et al. 2010). To maximize CNV discovery, we used multiple CNV
detection methods.
METHODS
Sample collection and genotyping
The study was approved by the Institutional Review Boards of Columbia
University and the University of Toronto. The Caribbean Hispanic case-
control dataset, consisting of participants predominantly originating
from the Dominican Republic and Puerto Rico, was described previously
(Lee JH et al. 2010). Brieﬂy, the dataset included 559 unrelated cases
with late-onset AD and 554 unrelated controls similar in age and sex
distribution. The mean (SD) age at onset of AD was 80.0 (8.0) years, and
the mean (SD) age at last examination of the controls was 78.9 (6.4)
years. In both the control and AD groups, 70% of the participants were
women. The diagnosis of AD was based on the National Institute of
Neurological Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association criteria (McKhann et al.1 9 8 4 ) .
All DNA samples were isolated from whole blood and were
randomly distributed in genotyping plates. All samples were
genotyped on Illumina HumanHap 650Y arrays at the same
laboratory. The dataset consisted only of samples that previously
passed SNP-based quality control procedures (e.g. gender miscalls
and relatedness checks) (Lee JH et al. 2010). Our preliminary anal-
ysis was done as a blind study, and the affection status of the
samples was only disclosed after the CNV detection procedures
were completed.
Quality control and CNV detection
Raw intensity array data were normalized within and across samples
using Illumina’s BeadStudio software v.3.3.7. To maximize CNV dis-
covery, we ran four different CNV calling algorithms, QuantiSNP
(Colella et al. 2007), iPattern (Pinto et al. 2011), PennCNV (Wang
et al. 2007), and CNVpartition (implemented in BeadStudio). To
obtain high-conﬁdence CNV calls, a stringent CNV dataset was gen-
erated by taking the CNV calls by iPattern that were also found by
at least one additional algorithm (either PennCNV or QuantiSNP).
Speciﬁcally, each CNV detected by two methods was merged using the
outside probe boundaries (i.e. union of the CNVs) as described pre-
viously (Pinto et al. 2010), and it needed to overlap in at least 50%
of its length. Previously (using Illumina 1M arrays) we showed that
stringent CNVs .30 kb detected by both iPattern and QuantiSNP
were conﬁrmed by quantitative PCR (qPCR) to be true events at
95% conﬁdence (Pinto et al. 2010). Here, given the lower resolution
of the current 650K array, we assumed that a comparable sensitivity
would be able to detect large CNVs (.100 kb). To minimize over-
estimation of reported boundaries, the third algorithm was only used
for support. The fourth algorithm, CNV partition, was used to visu-
alize large CNVs.
Poor quality samples were excluded from the study if they met the
following criteria: chip call rate , 97%; log R ratio standard deviation
. 0.27; B allele frequency standard deviation . 0.17; and PennCNV
wave factor . 0.04 or # 0.04 (Diskin et al. 2008). We excluded CNV
calls when they failed stringent quality control (QC) criteria: ,5
probes, ,100 kb size, or low conﬁdence QuantiSNP score (log Bayes
factor , 15), as these CNVs were likely to be unreliable at the current
array resolution. We also excluded CNV calls within hypervariable
centromere proximal bands and those overlapping immunoglobulin
regions, as both are known to be prone to artifactual CNV calling and
thus false discoveries.
Finally, we removed samples that had an excessive number of
CNVs detected by each algorithm (i.e. samples with a number of CNV
calls exceeding the third quartile plus three times the interquartile
range). The resulting cutoff for the number of CNVs per sample
was 67 CNV calls for PennCNV, 35 calls for QuantiSNP, and 35 calls
for iPattern. Chromosome X and all CNVs . 1 Mb detected by any
algorithm were inspected manually. Samples with excessive aggregate
length of CNVs, as well as samples with CNVs . 7.5 Mb (likely
karyotyping abnormalities) were visually inspected by plotting their
intensities and allelic ratios, and removed from burden analyses (sup-
porting information, Table S1).
For the purpose of burden analysis, CNVs with more than 50% of
their length overlapping segmental duplications were discarded; CNVs
found in .1% of cases and controls were not considered further. A
total of 392 cases (106 males, 286 females) and 357 controls (104
males, 253 females) passed all QC steps and were used in subsequent
analyses. The female/male ratio and age at onset in the dataset that
passed all QC steps remained similar to original dataset:  70%
females, the mean age at onset (SD) of AD cases was 77.1 (8.5) years,
and the mean age at last examination (SD) of the controls was 79.5
(6.1) years.
CNV burden analyses
To determine whether cases show a greater genome-wide burden of
rare CNVs compared with controls, CNV burden analyses were
conducted using PLINK v1.07 and a permutation procedure (one-
sided, 100,000 permutations) (Purcell et al. 2007). P values were esti-
mated for the number of CNVs per individual (CNV rate), for CNV
sample proportion (fraction of samples with one or more CNVs), and
72 | M. Ghani et al.for the total or average size ranges of CNV calls. Genome-wide P
values were further corrected (Pcorr) for potential global case-control
differences in CNV rate and size. CNVs found to be enriched in AD
cases compared with controls or found only in AD cases were further
evaluated by comparison with the Database of Genomic Variants
(DGV), a catalog of CNVs found in control subjects of diverse pop-
ulations, and by comparison with 5000 Caucasian controls previously
used in an autism CNV study (Pinto et al. 2010). However, the con-
trols in the autism study and DGV database were not speciﬁcally
screened for AD symptoms.
CNV validation
Primers for qPCR were designed using the Primer3 software. The
samples were screened for dosage aberrations using qPCR, amplifying
5 ng of DNA with SYBR Green reagent (TaKaRa Mirus Bio, Madison,
WI) on an ABI7500 system (Applied Biosystems, Foster City, CA).
The duplication at 15q11.2 was assessed with two sets of primers
targeting the NIPA1 and CYFIP1 genes: (1) (NIPA1-F) 59-tctcctgaag-
gaaaagctcaa and (NIPA1-R) 59-ctcagactttggggagtgga; (2) (CYFIP1-F)
59-aggccaaccacaacgtgtc and (CYFIP1-R) 59-agcagtagttgggcaggaag. The
beta-globin gene (HBB) was used as the endogenous control: (HBB-F)
59-gcaacctcaaacagacacca and (HBB-R) 59-cctcaccaccaacttcatcc. An un-
related control DNA sample without this CNV was used as a calibra-
tion sample. The relative dosage (in triplicate) was determined by the
comparative threshold cycle method (ddCt) implemented in the ABI
Prism sequence detection software (v.1.3.1).
RESULTS
CNV characteristics
Overall, we detected 1774 stringent CNVs with sizes $100 kb in the
392 cases and 357 controls that passed the QC steps (mean size ¼
252,651 bp; median size ¼ 176,893 bp). This stringent CNV dataset
was composed of 932 CNV calls in cases (52.5%) and 842 calls in
controls (47.5%). We did not observe signiﬁcant differences in the
number of deletions between cases (n ¼ 397; 22.4%) and controls
(n ¼ 367; 20.7%) or in the number of duplications between cases
(n ¼ 535; 30.2%) and controls (n ¼ 475; 26.8%). Hence, there was
no signiﬁcant global enrichment between cases and controls for the
total number of CNV calls or for deletions or duplications. However,
we observed a nominal association between AD and a  470 kb (20.3–
20.7 Mb NCBI36/hg18) duplication on chr15q11.2 (x2 ¼ 3.206; un-
corrected one-tailed P ¼ 0.037). This duplication, encompassing up to
ﬁve genes (TUBGCP5, CYFIP1, NIPA2, NIPA1,a n dWHAMML1)a n d
ﬂanked by two low-copy repeats BP1–BP2, was present in 10 cases
(2.6%) and in 3 controls (0.8%). The dosage increase of the CYFIP1
and NIPA1 genes in AD patients was further conﬁrmed by qPCR
(Figure S1).
Analyses of large rare CNVs
A total of 734 stringent rare CNVs $ 100 kb with a frequency # 1%
in the total sample set were observed in our dataset (mean size ¼
292,240 bp; median size ¼ 200,981 bp), including 277 deletions and
457 duplications (Table 1, Table S2). Three hundred ninety (390) rare
large CNVs were detected in 255 cases (65.0%), and 344 of these
CNVs were found in 224 controls (62.7%) (case/control ratio ¼
1.03; P ¼ 0.35) (Table S2). We did not detect signiﬁcant differences
in the distribution of large rare deletions or duplications between cases
and controls (Table 1). Furthermore, no signiﬁcant association with
AD was found in the total size of rare CNVs (case/control ratio ¼
0.94; P ¼ 0.77). Similarly the average size of rare CNVs was not
different between cases and controls (case/control ratio ¼ 0.88; P ¼
0.94) (Table 1).
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Volume 2 January 2012 | Copy Number Variants in AD | 73Global burden analyses were further extended by stratifying rare
CNVs according to size (e.g. .500 kb or .1 Mb) and CNVs with
genic content. None of these strategies revealed signiﬁcant differences
between cases and controls (Tables 1 and 2). For instance, the case/
control ratio for all genic CNVs was 0.94 (1.1 for deletions and 0.9 for
duplications), and no considerable enrichment was found for CNV
size in any range or excess of gene-disrupting CNVs (Tables 1 and 2).
Candidate novel CNVs
We observed 12 CNVs .1 Mb that were detected in eight AD cases
and four controls. Six CNVs were found only in AD cases and were
observed neither in Hispanic controls nor in the DGV (Table S3),
suggesting that they might be novel structural abnormalities with
potential functional signiﬁcance for AD. For example, in case
NY1811 (age at onset 73), we observed a 1.9 Mb duplication on chr
2p16.3 (Figure S2A) encompassing the entire neurexin1 gene
(NRXN1) that encodes a neuronal cell surface protein involved in cell
recognition and cell adhesion. Genome-wide CNV studies previously
implicated NRXN1 deletions in autism and schizophrenia (Ching et al.
2010; Magri et al. 2010). Our study is the ﬁrst report describing
a duplication of NRXN1 in an AD case.
In AD case NY1261 (age at onset 89), we detected a 1.4 Mb deletion
on chromosome 17p13.1-2 and a 563 kb deletion on 3p21.31 (Figure
S2B). Together both deletions affect 90 genes, including several genes
implicated in synaptic function (DLG4, NLGN2, CHRNB1, GABARAP,
and PITPNM3)( Table S2). In AD case RX1107 (age at onset 88), we
detected a 2.9 Mb deletion on chromosome 7q35-q36.1 (Figure S2C)
that disrupts the CNTNAP2 gene encoding the contactin-associated
protein-like 2 protein, a member of the neurexin family that medi-
ates interactions between neurons and glial cells. SNPs in the
CNTNAP2 were reported to be signiﬁcantly associated with schizo-
phrenia and bipolar disorder in GWAS studies (Wang et al. 2010;
O’Dushlaine et al. 2011). Intriguingly, variants in CNTNAP2 were
also implicated in pseudoexfoliation syndrome (Krumbiegel et al.
2011) among patients who show a selective downregulation of clus-
terin (CLU) expression in their eyes (Zenkel et al. 2006). Notably,
the association between CLU SNPs and AD was conﬁrmed in several
studies at a genome-wide signiﬁcance level (Harold et al. 2009;
Lambert et al. 2009; Carrasquillo et al. 2010).
In addition, we generated a list of 29 genes that were affected by
CNVs in two or more AD patients, that were not seen in our
Caribbean Hispanic controls, and that were absent or rare in the DGV
and 5000 Caucasian controls (Table 3). Some of these genes
have potential functional connections to neurological disorders. For
instance, in two AD patients, we detected deletions affecting the
protein-tyrosine phosphatase receptor-type delta gene (PTPRD),
which has been associated with restless legs syndrome (Morris et al.
2010; Yang et al. 2011). One of the deletions (128 kb) removes exon 9
of PTPRD, and the other one (135 kb) removes exon 4. Also, two
patients (RM4073 and RM4285) had a 622 kb duplication on chr
5q12.1 affecting ﬁve genes, including the NDUFAF2 gene that encodes
a chaperone for mitochondrial complex I assembly and that was
found to be implicated in attention-deﬁcit/hyperactivity disorder
(Lesch et al. 2011). Two other duplications were detected at 3p26.3,
disrupting the contactin 6 gene (CNTN6). Structural and sequence
variations in several members of the contactin gene family were as-
sociated with neuropsychiatric disorders (e.g. schizophrenia and au-
tism) (Fernandez et al. 2008; Burbach and van der Zwaag 2009;
Cottrell et al. 2011).
DISCUSSION
We conducted a genome-wide scan for large CNVs ($100 kb) in
a case-control dataset of Caribbean Hispanic origin that was previ-
ously investigated in a SNP-based GWAS (Lee JH et al. 2010). To
generate results with high conﬁdence, we focused on CNVs that were
identiﬁed by at least two algorithms. We detected 1774 stringent
CNVs (Table S4). First, we tested the hypothesis that rare CNVs
(#1%) with a potentially strong impact on AD risk in individual
patients might contribute to the overall disease risk, as was previously
observed in other common neuropsychiatric disorders (Kirov et al.
2009; Zhang et al. 2009; Glessner et al. 2010). However, the burden
analyses of rare CNVs did not ﬁnd signiﬁcant differences between
cases and controls in CNV rate, total or average CNV size, or the
number of genes affected by CNVs.
In addition, we conducted a case-control analysis of large genic
CNVs, including common variants, using PLINK regional analysis.
The only nominally signiﬁcant result that survived qPCR conﬁrma-
tion was detected for a duplication on chromosome 15q11.2 affecting
up to ﬁve genes, including NIPA1 and CYFIP1 (P ¼ 0.037). Duplica-
tions affecting the NIPA1 and CYFIP1 in control populations
are cataloged at the DGV based on four studies (Pinto et al. 2007;
Zogopoulos et al. 2007; Itsara et al. 2009; Shaikh et al. 2009) with
similar frequencies to our controls (0.5%): this duplication was
reported in 24 out of 5056 individuals.
n Table 2 Global rare CNV burden: gene count in 392 cases vs. 357 controls
Type Classiﬁcation P Case/Control Ratio Baseline Rate (Controls) Pcorr
None
All All 0.6138 0.9443 1.796 0.8109
Deletions only All 0.3441 1.1552 0.4902 0.4745
Duplications only All 0.8136 0.8659 1.305 0.3639
CNV size
All 100–500 kb 0.6251 0.9599 1.148 0.5227
$ 500 kb 0.5694 0.9186 0.6471 0.9987
$ 1 Mb 0.5166 0.9555 0.2857 0.5154
Deletions only 100–500 kb 0.3937 1.0928 0.2521 0.9470
$ 500 kb 0.2965 1.2213 0.2381 0.5682
$ 1 Mb 0.6019 0.8995 0.2269 0.6848
Duplications only 100–500 kb 0.6976 0.9220 0.8964 0.4880
$ 500 kb 0.7764 0.7423 0.409 0.4356
$ 1 Mb 0.4459 1.1710 0.05882 0.5912
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76 | M. Ghani et al.NIPA1 encodes a magnesium transporter associated with early
endosomes in neuronal and epithelial cells (Rainier et al. 2003; van
der Zwaag et al. 2010). CYFIP1 forms a complex at synapses with the
fragile X mental retardation protein (FMRP) and eIF4E (FMRP-
CYFIP1-eIF4E complex). FMRP acts as an APP translation repressor
(Lee EK et al. 2010), releasing CYFIP1 from the FMRP-CYFIP1-eIF4E
complex in response to synaptic stimulation (Napoli et al. 2008).
Therefore, unbalanced dosage of CYFIP1 might result in altered
APP turnover in AD patients. Of note, this region belongs to a larger
region at chromosome 15q11-q13 that has been introduced as one of
the most reliable “cytogenetic regions of interest” for genomic aberra-
tions in autism spectrum disorders (Vorstman et al. 2006). It is im-
portant that the association between AD and the 15q11.2 duplication
be validated in follow-up studies using large case-control datasets.
Our study does not support the previously reported marginal
association between AD and the  500 kb duplication on chromosome
15q13.3 affecting the CHRNA7 locus in a genome-wide scan of a North
American dataset (Heinzen et al. 2010), which is 9.5 Mb away from the
duplication on 15q11.2 discussed above. We observed an equal number
of cases (n ¼ 2; 0.5%) and controls (n ¼ 2; 0.6%) with duplications
affecting CHRNA7,w h e r e a sH e i z e net al. detected this CNV in six
cases (2%) and one control (0.3%) (Heinzen et al. 2010).
In addition, a higher copy number of a complex multiallelic
segment (DGV variation_0316) containing the olfactory receptor genes
on chromosome 14q11.2 was reported to be associated with a decrease
in age at onset of AD using genotypes obtained from Affymetrix SNP
6.0 arrays (controls were not evaluated) (Shaw et al.2 0 1 1 ) .A l t h o u g h
this region is  200 kb in size, it is poorly covered with SNPs in the
650Y array used for our study (three SNPs). Therefore, we were unable
to assess the contribution of this region to AD in our dataset.
We did not detect CNVs (including common variants) that affect
the well-conﬁrmed AD loci reported by large GWAS (CLU, PICALM,
BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33, EPHA1,a n dABCA7)
(Harold et al. 2009; Lambert et al. 2009; Carrasquillo et al. 2010;
Hollingworth et al. 2011; Naj et al. 2011). However, as the array
technology used in the current study has limitations in detecting small
CNVs, future studies must carefully assess the new AD loci using
a qPCR approach to detect small CNVs. For instance, by using mul-
tiplex amplicon quantiﬁcation, a recent study reported that an  18 kb
CNV in the CR1 gene is associated with AD risk and could explain the
strong association between AD and SNPs at the CR1 locus detected by
GWAS (Brouwers et al. 2011).
The limitations of our study are the modest dataset size and the
fact that the study was not designed for the comprehensive detection
of common CNVs. Several analytical challenges in the detection of
common CNVs from SNP-intensity data could lead to a high false
negative/positive rate. In general, a case-control setting can only test
clusterable common CNVs that are well-tagged by common SNPs and
are thus effectively screened by SNP-based GWAS (e.g. CR1 study
discussed above (Brouwers et al. 2011)). On the other hand, the
unclusterable CNVs could be of a multiallelic or complex nature
(e.g. a small deletion within a large CNV duplication) and can only
be accurately genotyped using a combination of custom arrays and
deep sequencing. Nevertheless, we observed several reliably detected
common CNVs that were included in a case-control analysis of genic
CNVs (e.g. CNV on 15q11.2). Notably, none of the most signif-
icant variations previously detected in our SNP-based Hispanic
GWAS (P , 1025)( L e eJ Het al. 2010) tag any of the common CNVs
identiﬁed in the current study.
In summary, in a stringent genome-wide investigation for the
global burden enrichment of large rare CNVs, we didn’t ﬁnd any
signiﬁcant difference between AD cases and controls. However, this
ﬁnding may indicate the requirement of larger datasets to identify the
enrichment of any of the above-mentioned CNVs. Similarly, conﬁr-
mation of the biological signiﬁcance of several large CNVs found only
in AD patients requires further assessment in large cohorts, as well as
functional studies. Nevertheless, modest datasets, such as reported
here, can be useful for identifying rare variants for further validation
in follow-up studies.
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